SUPPLEMENTARY DATA



Supplementary Figure 1. Lethality of different *C. albicans* inocula in CD1 mice. (**A**) Survival percentage over time of CD1 mice infected (*i.v.*) with different *C. albicans* inocula (3 x 10^2 CFU/g, n = 6; 3 x 10^3 CFU/g, n = 6; 3 x 10^4 CFU/g, n = 5). (**B**) Survival percentage over time of CD1 mice infected with *C. albicans* (3 x 10^4 CFU/g, *i.v.*) and treated with single HSA (n = 27) or shCD5 doses (1.25 mg/kg, *i.v.*) at different time points (hours) post-infection (+1h, n = 8; +9h, n = 19; +18h n = 9). Statistical differences between groups were analyzed by Log-rank (Mantel-Cox) test.*, $P \leq 0.05$; ****, $P \leq 0.0001$.

Supplementary Figure 2



Supplementary Figure 2. Effect of shCD5 infusion on serum cytokine levels and spleen leukocyte infiltration from *C. albicans*-infected CD1 mice. (**A**) Serum cytokine levels at 72 h post-infection of CD1 mice with *C. albicans* (3 x 10^3 CFU/g, *i.v.*) and treated (*i.v.*) with single 1.25 mg/kg dose of HSA (n = 7) or shCD5 (n = 7) at 18 h post-infection. Represented are fold inductions with regard to non-infected mice (basal, n = 4). (**B**) Total leukocyte ($CD45^+$), B ($B220^+CD3^-$), T ($CD3^+B220^-$), natural killer (NK, $NK1.1^+CD3^-$) granulocytes (Gr, $Gr\text{-}1^+SSC^{hi}$), conventional dendritic cells (cDCs, $CD11c^+B220^-$), and macrophage (Mϕ, $CD11c^-Gr\text{-}1^{low}SSC^{low}$) cell numbers assessed by flow cytometry from the same mice as in **A**. Statistical differences between groups were analysed by Kruskal–Wallis and Dunn's test.*, $P \leq 0.05$.

Supplementary Figure 3



Supplementary Figure 3. Lethality of different *C. albicans* inocula in immunodeficient NSG mice. Survival percentage over time of NSG mice infected (*i.v.*) with different *C. albicans* inocula (3×10^2 CFU/g, n = 5; 3×10^3 CFU/g, n = 4; 3×10^4 CFU/g, n = 5).

Supplementary Fig. 4



Supplementary Figure 4. Dose-response effects of fluconazole in *C. albicans*-infected mice. Survival percentage over time of CD1 mice infected with *C. albicans* (3 x 10^3 CFU/g, *i.v.*) and treated daily (*i.p.*) for 1 week with vehicle (n = 4) or different fluconazole doses (FCL, 10 mg/kg, n = 4; 1 mg/kg, n = 4; 0.1 mg/kg, n = 4) starting at 48 h post infection.

Supplementary Figure 5



Figure 5. ***Ex vivo*** **analysis of shCD5-mediated anti-cryptococcal effects.** (**A**) Percentage of killed *C. neoformans* following 2 h co-cultivation of total CD1 splenocytes (10^6 cells/mL) with live *C. neoformans* (0.5 x 10^6 CFU/mL) in the presence of vehicle or shCD5 (1 or 10 μg/mL). Results are the mean ± SEM from n = 10 mice. (**B**) Percent of viable *C. neoformans* following 2 h exposure of live *C. neoformans* (0.5 x 10^6 CFU/mL) to vehicle or shCD5 (1 or 10 mg/mL). Results are the mean ± SD of 6 replicates. Statistical differences between groups were analysed by Kruskal–Wallis and Dunn's test.*, $P \leq 0.05$.